Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
NCT ID: NCT05575440
Last Updated: 2025-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
24 participants
OBSERVATIONAL
2022-04-22
2028-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer
NCT03196518
Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer
NCT00647140
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
NCT05534594
Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma
NCT01374659
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
NCT01610544
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Evaluate fluorine F 18 tetrafluoroborate (18F-TFB) positron emission tomography (PET)/computed tomography (CT) imaging in patients with intermediate or high risk differentiated thyroid cancer (DTC) and compare to the current clinical standard.
II. Assess the impact of 18F-TFB PET/CT on clinical management.
OUTLINE:
Patients receive fluorine F 18 tetrafluoroborate intravenously (IV) and undergo PET/CT scan on study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational (18F-TFB PET/CT)
Patients receive fluorine F18 tetrafluoroborate IV and undergo PET/CT scan on study.
Computed Tomography
Undergo a PET/CT scan
Fluorine F 18 Tetrafluoroborate
Given IV
Positron Emission Tomography
Undergo a PET/CT scan
Survey Administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Computed Tomography
Undergo a PET/CT scan
Fluorine F 18 Tetrafluoroborate
Given IV
Positron Emission Tomography
Undergo a PET/CT scan
Survey Administration
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is clinically indicated for 123I-SPECT/CT total body iodine (TBI) scan
* Subject agrees to undergo 18F-TFB PET/CT scan following TBI scan
* Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] equivalent)
* Subject is able to be scanned - able to lie still on SPECT/CT and PET/CT scanner table for up to 65 minutes (min)
* Age 18 or older
* Ability to understand a written informed consent document, and the willingness to sign it
* Subject is not pregnant
Exclusion Criteria
* Amiodarone within last 4 months
* Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks
* Unable to lie flat, still or tolerate a PET scan
* Applied betadine, iodoform, or quick tanning products to skin within last two weeks
* If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \< 25
* Taken anti-thyroid medication within 1 week
* Subject is breastfeeding
* Positive pregnancy test
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen M. Broski, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic in Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-010573
Identifier Type: -
Identifier Source: org_study_id
NCI-2022-03071
Identifier Type: REGISTRY
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.